Fused Spirocycle Compounds for Selective N-Type Calcium Channel Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current calcium channel blockers lack selectivity for N-type channels over L-type channels, leading to potential hypotensive effects and limiting their neuroprotective and analgesic efficacy.
Innovation Solution
Development of novel fused and spirocycle compounds represented by Formula I, which act as selective N-type calcium channel blockers, offering a pharmaceutical composition for treating various disorders by modulating calcium channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current calcium channel blockers are used to block calcium channels, then neuroprotective and analgesic effects are achieved, but hypotensive effects occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (fused and spirocycle moieties) that confer selective affinity for N-type calcium channels. The molecular structure incorporates particular substituents and ring systems that target the unique binding site of N-type channels, allowing the drug to exert neuroprotective effects without blocking L-type channels in the heart and blood vessels, thereby avoiding hypotension.
Solution Approach 2:
The patent employs parameter changes by optimizing key molecular parameters including the type of fused ring system (isobenzofuran, indene, indane), the nature of substituents at different positions, and the configuration of spirocycle structures. These structural parameter variations systematically tune the compound's selectivity profile to preferentially bind N-type calcium channels over L-type channels, resolving the contradiction between efficacy and side effects.
2Adaptability or versatility
If non-selective calcium channel blockers are administered, then broad calcium channel inhibition occurs, but therapeutic selectivity for N-type channels is lost
Solution Approach 1:
The patent applies segmentation by dividing the calcium channel blocker market into type-specific agents. Instead of developing a single broad-spectrum blocker, the invention creates compounds specifically segmented for N-type channel selectivity through unique structural motifs. This segmentation allows precise targeting of neuronal N-type channels while leaving cardiac L-type channels unaffected, achieving both versatility in application and precision in selectivity.
3Reliability
If L-type calcium channels are inhibited for neuroprotection, then neuronal protection is enhanced, but cardiac function is compromised due to hypotension
Solution Approach 1:
The patent uses the concept of an intermediary by introducing a selective N-type calcium channel blocker as a mediator between neuroprotective needs and cardiac safety. These compounds act as selective intermediaries that block calcium influx specifically at N-type channels in the nervous system, providing neuroprotection without interfering with L-type channel-mediated calcium signaling in the heart, thus maintaining cardiac function while achieving neurological benefits.
Data Source
AI summary
The invention relates to fused and spirocycle compounds of Formula I:or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1, R2, Q1-Q3, and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.